Bicara Therapeutics develops ficerafusp alfa, an investigational antibody therapy for solid tumors such as head and neck cancers. It last closed at $8.44 on Nov 20, down 7.46% on the day. The next earnings report for BCAX is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, BCAX reported EPS of -$1.04. Over its last 8 reports the stock moved an average of 6.6% the session after earnings. Over the last 12 months BCAX insiders bought $4.8M of stock on the open market and sold $9.9M, according to SEC Form 4 filings.
AI Auto Pilots
Is BCAX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BCAX.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on BCAXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
BCAX · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 20% below its 20 day and 83% below its 50 day average. It is 145% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot S1 at $8.20, and the nearest resistance the Pivot at $8.67.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.2%/day
Key levels
$30.9952 week high+267.2%
$20.72100 day average+145.5%
$20.65200 day average+144.7%
$15.4350 day average+82.8%
$11.45Swing high (Nov 11)+35.7%
$10.1420 day average+20.1%
$8.91Pivot R1+5.6%
$8.67Pivot+2.7%
$8.44Last close
$8.20Pivot S1−2.8%
$7.8752 week low−6.8%
$7.87Swing low (Nov 2)−6.8%
Indicators
RSI (14)
28.24
Oversold below 30
Oversold
MACD
-1.89
Above its signal line
Bullish
Stochastic
30.8
Middle of its range
Neutral
ADX (14)
47.2
Strong downtrend
Williams %R
-84.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-66.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−2.4%
Change over 10 sessions
Bearish
ATR (14)
$1.03
Typical daily range, 12.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityHigh, 34.3%/day
Key levels
$30.9952 week high+267.2%
$20.72100 day average+145.5%
$20.65200 day average+144.7%
$15.4350 day average+82.8%
$11.45Swing high (Nov 11)+35.7%
$10.1420 day average+20.1%
$8.91Pivot R1+5.6%
$8.67Pivot+2.7%
$8.44Last close
$8.20Pivot S1−2.8%
$7.8752 week low−6.8%
$7.87Swing low (Nov 2)−6.8%
Indicators
RSI (14)
24.89
Oversold below 30
Oversold
MACD
-3.26
Below its signal line
Bearish
Stochastic
5.8
Near the bottom of its range
Oversold
ADX (14)
29.1
Trending down
Williams %R
-97.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-140.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−63.0%
Change over 10 sessions
Bearish
ATR (14)
$2.89
Typical daily range, 34.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for BCAX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how BCAX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for BCAXHow many large options trades hit BCAX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in BCAX in the last 90 days.
From SEC Form 4 filings by BCAX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BCAX is in one of them and how their past BCAX trades turned out.
Bicara Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that is developing treatments for solid tumors. Its main candidate, ficerafusp alfa, is an investigational antibody that pairs an antibody targeting the EGFR protein on tumor cells with a molecule that blocks TGF-β, a signaling protein that helps tumors resist treatment. The candidate is being tested mainly in head and neck squamous cell carcinoma, and the company does not yet sell a product. Its intended patients are people with solid tumors, starting with head and neck cancers.